Abstract 285P
Background
Adjuvant ET reduces breast cancer recurrence and increases overall survival among patients with early-stage ER+ breast cancer, however a suboptimal number of patients older than 65 years are included in the studies. This study aims to evaluate adherence to adjuvant ET and sexual dysfunction in women >65 years old with early breast cancer.
Methods
Women with a history of early-stage ER+ invasive carcinoma of the breast on adjuvant ET for at least 6 months were invited to participate. Adherence was assessed with Morisky Medication Adherence Scale (MMAS-8). Quality of life was assessed using EORTC QLQ C30 and BR-23 forms. Sexuality was assessed with the Female Sex Function Index questionnaire. Patients were stratified according to age <=65 years and > 65 years old. Qualitative variables were compared between groups using the Chi-square or exact Chi-square test and for quantitative variables the non-parametric Mann-Whitney test was used.
Results
From June 2021 to March 2024, 774 women from 15 Brazilian institutions were recruited. Mean age was 62 y.o, mean tumor size was 2.24 cm, mean duration of ET was 3.2y. About 191 patients (24.7%) were older than 65y, 69.6% of them were high adherent to ET and 70.7% had sexual dysfunction. In comparison with women <=65 y.o, older women were associated with private healthcare insurance (p=0.003), living with no partner (p < 0.0001), prior lumpectomy (p = 0.0017), prior sentinel node biopsy (p = 0.03), no prior chemotherapy (p < 0.0001), use of aromatase inhibitors (p < 0.0001) and use of concomitant medications (p < 0,0001). Patients older than 65 years were more associated with lower adherence (p = 0.0009), but there was no difference in sexual dysfunction in comparison with patients less than 65 y. Patients over 65 years had significantly higher scores for Emotional Functioning, Cognitive Functioning, Social Functioning, Body Image and Future Perspective domains of quality of life.
Conclusions
Patients older than 65 y.o had less aggressive treatments, many better domains in quality of life, but lower adherence to ET than patients aged up to 65 years. An important issue for womens’ health is sexual health and in this context, sexual dysfunction affects women besides age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
323P - SPEN: Unraveling breast cancer's genetic symphony — Prognostic significance and therapeutic insights
Presenter: Sameer Emeish
Session: Poster session 14
324P - Application of advanced machine learning techniques to improve prognosis in primary breast angiosarcoma
Presenter: Haya Kamal
Session: Poster session 14
Resources:
Abstract
325P - The clinical validity of histological grade in neoadjuvant treated breast cancer
Presenter: Sanna Steen
Session: Poster session 14
326P - Exploratory analysis of the association of systemic inflammation and breast cancer recurrence in the Optitrain randomised controlled trial
Presenter: Marlene Rietz
Session: Poster session 14
327P - Monitoring over time of pathological complete response to neoadjuvant chemotherapy in breast cancer patients through an ensemble vision transformers-based model
Presenter: Maria Colomba Comes
Session: Poster session 14
328P - Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results
Presenter: Daur Meretukov
Session: Poster session 14
329P - RANK/RANKL, ERBB-2: A putative dual targeting strategy in RANK+/Her2+ breast carcinomas patients
Presenter: Michalis Karamouzis
Session: Poster session 14
330P - Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients
Presenter: Shereef Elsamany Mohammed
Session: Poster session 14
331P - Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
Presenter: Mingxia Jiang
Session: Poster session 14
332P - Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab plus nab-paclitaxel followed by epirubicin/cyclophosphamide for TNBC: A phase II TREND trial
Presenter: yingying Xu
Session: Poster session 14